A Gene Editing Breakthrough
By Tom Ashbrook,
NPR On Point [features Marcy Darnovsky]
| 08. 08. 2017
After the blockbuster announcement a U.S. team successfully edited human embryos come the tough medical and ethical questions. We’ll talk it through.
A first in the U.S.: researchers have now edited the genetic code of viable human embryos, cutting and splicing to avoid defect and disease. The DNA of human embryos. Genetically edited. The edited embryos weren’t implanted in a woman. Weren’t born. But they could have been. New life spared disease, maybe death. How far does this gene editing go? How fast? For whom? And for, or against, what human traits? This hour On Point: editing the code of human life. -- Tom Ashbrook
Guests
Amy Dockser Marcus, health and science reporter for the Wall Street Journal. (@AmyDMarcus)
Dr. Paula Amato, co-author of the study showing successful editing of genes in human embryos. Associate professor of obstetrics and gynecology at Oregon Health & Science University.
Arthur Caplan, professor of bioethics and head of the division of medical ethics at the New York University School of Medicine. (@ArthurCaplan)
Marcy Darnovsky, executive director of...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
